The University of British Columbia

Provincial Health Services Authority

Essa Pharma, Inc.

Daniel Andrew Golec

Raymond John Andersen

Han-Jie Zhou

Peter Virsik

Marianne Dorothy Sadar

Kunzhong Jian

The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.

Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof

Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

Androgen receptor modulators and methods for their use

Growing community of inventors

Vancouver, Canada

Daniel Andrew Golec